Remove Gene Silencing Remove Hormones Remove Life Science Remove Medicine
article thumbnail

2020 review – Pharma’s progress outside of COVID-19

pharmaphorum

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. But there was some considerable progress in other fields of medicine even though research efforts were diverted away, reports Richard Staines. Rare disease progress.

article thumbnail

MHRA gives Alnylam ‘innovation passport’ for hypertension drug zilebesiran

pharmaphorum

The UK medicines regulator has awarded Alnylam’s RNAi-based therapy zilebesiran for hypertension an ‘innovation passport ‘, a designation designed to speed up NHS access to promising new medicines. The study is enrolling adults whose blood pressure is not adequately controlled by standard medicines.